These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9066005)

  • 1. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin.
    Brown NJ; Nadeau JH; Vaughan DE
    Thromb Haemost; 1997 Mar; 77(3):522-5. PubMed ID: 9066005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men.
    Pretorius M; Luther JM; Murphey LJ; Vaughan DE; Brown NJ
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2435-40. PubMed ID: 16166566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
    Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
    Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
    J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
    Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
    J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
    Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
    Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
    Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
    J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
    Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
    Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
    Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
    J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
    Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
    Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
    Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
    Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
    Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
    J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension.
    Korbut RA; Madej J; Adamek-Guzik T; Korbut R
    J Physiol Pharmacol; 2003 Sep; 54(3):397-408. PubMed ID: 14566078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
    Pretorius M; McFarlane JA; Vaughan DE; Brown NJ; Murphey LJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):379-87. PubMed ID: 15470338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.